These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 25003676)

  • 1. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum total antioxidant capacity to discriminate benign from malignant causes of biliary obstruction.
    Beyazıt Y; Koçak E; Tanoğlu A
    Turk J Gastroenterol; 2014 Oct; 25(5):592-3. PubMed ID: 25417631
    [No Abstract]   [Full Text] [Related]  

  • 3. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Author's reply: To PMID 25003676.
    Ince AT
    Turk J Gastroenterol; 2014 Oct; 25(5):593. PubMed ID: 25566599
    [No Abstract]   [Full Text] [Related]  

  • 5. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.
    Chen CY; Shiesh SC; Tsao HC; Lin XZ
    Hepatogastroenterology; 2002; 49(45):616-20. PubMed ID: 12063953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
    Alvaro D; Macarri G; Mancino MG; Marzioni M; Bragazzi M; Onori P; Corradini SG; Invernizzi P; Franchitto A; Attili AF; Gaudio E; Benedetti A
    Ann Intern Med; 2007 Oct; 147(7):451-9. PubMed ID: 17909206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
    World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions.
    Abdel-Razik A; ElMahdy Y; Hanafy EE; Elhelaly R; Elzehery R; M Tawfik A; Eldars W
    Am J Med Sci; 2016 Mar; 351(3):259-64. PubMed ID: 26992254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.
    Farina A; Dumonceau JM; Antinori P; Annessi-Ramseyer I; Frossard JL; Hochstrasser DF; Delhaye M; Lescuyer P
    Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
    Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
    Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
    Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
    Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
    Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L
    J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
    Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
    Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
    World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.